CEL-SCI Announces Proposed Public Offering of Common Stock

VIENNA, Va.--(BUSINESS WIRE)--$CVM--CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced that it intends to offer to sell shares of its common stock in an underwritten public offering. The Company expects to grant the underwriter a 45-day opti...

Related Keywords

Baltimore ,Maryland ,United States ,New York ,Vienna ,Wien ,Austria ,Virginia ,American , ,Exchange Commission ,Securities Exchange ,Orphan Drug Status ,Securities Act ,Securities Exchange Act ,Leukocyte Interleukin ,